Antidepressants- and antipsychotics-induced hepatotoxicity
Authorized Users Only
2021
Authors
Todorović Vukotić, NevenaĐorđević, Jelena
Pejić, Snežana
Đorđević, Neda O.
Pajović, Snežana B.
Review (Published version)
,
© 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature
Metadata
Show full item recordAbstract
Drug-induced liver injury (DILI) is a serious health burden. It has diverse clinical presentations that can escalate to acute liver failure. The worldwide increase in the use of psychotropic drugs, their long-term use on a daily basis, common comorbidities of psychiatric and metabolic disorders, and polypharmacy in psychiatric patients increase the incidence of psychotropics-induced DILI. During the last 2 decades, hepatotoxicity of various antidepressants (ADs) and antipsychotics (APs) received much attention. Comprehensive review and discussion of accumulated literature data concerning this issue are performed in this study, as hepatotoxic effects of most commonly prescribed ADs and APs are classified, described, and discussed. The review focuses on ADs and APs characterized by the risk of causing liver damage and highlights the ones found to cause life-threatening or severe DILI cases. In parallel, an overview of hepatic oxidative stress, inflammation, and steatosis underlying DILI ...is provided, followed by extensive review and discussion of the pathophysiology of AD- and AP-induced DILI revealed in case reports, and animal and in vitro studies. The consequences of some ADs and APs ability to affect drug-metabolizing enzymes and therefore provoke drug–drug interactions are also addressed. Continuous collecting of data on drugs, mechanisms, and risk factors for DILI, as well as critical data reviewing, is crucial for easier DILI diagnosis and more efficient risk assessment of AD- and AP-induced DILI. Higher awareness of ADs and APs hepatotoxicity is the prerequisite for their safe use and optimal dosing. © 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.
Keywords:
Hepatotoxicity / Antidepressants / Antipsychotics / Oxidative stress / Inflammation / SteatosisSource:
Archives of Toxicology, 2021, 95, 3, 767-789Funding / projects:
- Ministry of Science, Technological Development and Innovation of the Republic of Serbia, institutional funding - 200017 (University of Belgrade, Institute of Nuclear Sciences 'Vinča', Belgrade-Vinča) (RS-MESTD-inst-2020-200017)
- Ministry of Science, Technological Development and Innovation of the Republic of Serbia, institutional funding - 200178 (University of Belgrade, Faculty of Biology) (RS-MESTD-inst-2020-200178)
DOI: 10.1007/s00204-020-02963-4
ISSN: 0340-5761
PubMed: 33398419
WoS: 000604854800001
Scopus: 2-s2.0-85098800693
Institution/Community
VinčaTY - JOUR AU - Todorović Vukotić, Nevena AU - Đorđević, Jelena AU - Pejić, Snežana AU - Đorđević, Neda O. AU - Pajović, Snežana B. PY - 2021 UR - https://vinar.vin.bg.ac.rs/handle/123456789/9078 AB - Drug-induced liver injury (DILI) is a serious health burden. It has diverse clinical presentations that can escalate to acute liver failure. The worldwide increase in the use of psychotropic drugs, their long-term use on a daily basis, common comorbidities of psychiatric and metabolic disorders, and polypharmacy in psychiatric patients increase the incidence of psychotropics-induced DILI. During the last 2 decades, hepatotoxicity of various antidepressants (ADs) and antipsychotics (APs) received much attention. Comprehensive review and discussion of accumulated literature data concerning this issue are performed in this study, as hepatotoxic effects of most commonly prescribed ADs and APs are classified, described, and discussed. The review focuses on ADs and APs characterized by the risk of causing liver damage and highlights the ones found to cause life-threatening or severe DILI cases. In parallel, an overview of hepatic oxidative stress, inflammation, and steatosis underlying DILI is provided, followed by extensive review and discussion of the pathophysiology of AD- and AP-induced DILI revealed in case reports, and animal and in vitro studies. The consequences of some ADs and APs ability to affect drug-metabolizing enzymes and therefore provoke drug–drug interactions are also addressed. Continuous collecting of data on drugs, mechanisms, and risk factors for DILI, as well as critical data reviewing, is crucial for easier DILI diagnosis and more efficient risk assessment of AD- and AP-induced DILI. Higher awareness of ADs and APs hepatotoxicity is the prerequisite for their safe use and optimal dosing. © 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature. T2 - Archives of Toxicology T1 - Antidepressants- and antipsychotics-induced hepatotoxicity VL - 95 IS - 3 SP - 767 EP - 789 DO - 10.1007/s00204-020-02963-4 ER -
@article{ author = "Todorović Vukotić, Nevena and Đorđević, Jelena and Pejić, Snežana and Đorđević, Neda O. and Pajović, Snežana B.", year = "2021", abstract = "Drug-induced liver injury (DILI) is a serious health burden. It has diverse clinical presentations that can escalate to acute liver failure. The worldwide increase in the use of psychotropic drugs, their long-term use on a daily basis, common comorbidities of psychiatric and metabolic disorders, and polypharmacy in psychiatric patients increase the incidence of psychotropics-induced DILI. During the last 2 decades, hepatotoxicity of various antidepressants (ADs) and antipsychotics (APs) received much attention. Comprehensive review and discussion of accumulated literature data concerning this issue are performed in this study, as hepatotoxic effects of most commonly prescribed ADs and APs are classified, described, and discussed. The review focuses on ADs and APs characterized by the risk of causing liver damage and highlights the ones found to cause life-threatening or severe DILI cases. In parallel, an overview of hepatic oxidative stress, inflammation, and steatosis underlying DILI is provided, followed by extensive review and discussion of the pathophysiology of AD- and AP-induced DILI revealed in case reports, and animal and in vitro studies. The consequences of some ADs and APs ability to affect drug-metabolizing enzymes and therefore provoke drug–drug interactions are also addressed. Continuous collecting of data on drugs, mechanisms, and risk factors for DILI, as well as critical data reviewing, is crucial for easier DILI diagnosis and more efficient risk assessment of AD- and AP-induced DILI. Higher awareness of ADs and APs hepatotoxicity is the prerequisite for their safe use and optimal dosing. © 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.", journal = "Archives of Toxicology", title = "Antidepressants- and antipsychotics-induced hepatotoxicity", volume = "95", number = "3", pages = "767-789", doi = "10.1007/s00204-020-02963-4" }
Todorović Vukotić, N., Đorđević, J., Pejić, S., Đorđević, N. O.,& Pajović, S. B.. (2021). Antidepressants- and antipsychotics-induced hepatotoxicity. in Archives of Toxicology, 95(3), 767-789. https://doi.org/10.1007/s00204-020-02963-4
Todorović Vukotić N, Đorđević J, Pejić S, Đorđević NO, Pajović SB. Antidepressants- and antipsychotics-induced hepatotoxicity. in Archives of Toxicology. 2021;95(3):767-789. doi:10.1007/s00204-020-02963-4 .
Todorović Vukotić, Nevena, Đorđević, Jelena, Pejić, Snežana, Đorđević, Neda O., Pajović, Snežana B., "Antidepressants- and antipsychotics-induced hepatotoxicity" in Archives of Toxicology, 95, no. 3 (2021):767-789, https://doi.org/10.1007/s00204-020-02963-4 . .